TY  - JOUR
AU  - Alés-Martínez, José Enrique
AU  - Balmaña, Judith
AU  - Sánchez-Rovira, Pedro
AU  - Salvador Bofill, Francisco Javier
AU  - García Sáenz, Jose Ángel
AU  - Pimentel, Isabel
AU  - Morales, Serafín
AU  - Fernández-Abad, María
AU  - Lahuerta Martínez, Ainhara
AU  - Ferrer, Neus
AU  - Zamora, Pilar
AU  - Bermejo, Begoña
AU  - Díaz-Redondo, Tamara
AU  - López-Ceballos, María Helena
AU  - Galan Gramaje, Maria
AU  - Pérez-Escuredo, Jhudit
AU  - Calabuig, Laura
AU  - Sampayo, Miguel
AU  - Pérez-Garcia, José Manuel
AU  - Cortés, Javier
AU  - Llombart-Cussac, Antonio
PY  - 2024
DO  - 10.1016/j.breast.2024.103780
UR  - https://hdl.handle.net/20.500.13003/21121
T2  - Breast (Edinburgh, Scotland)
AB  - To evaluate the efficacy and safety of the combination of olaparib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC) and germinal BRCA mutations (gBRCAm).OPHELIA (NCT03931551) was a single-arm, open-label, phase 2 clinical...
LA  - eng
M2  - 103780
PB  - Elsevier
KW  - Breast Neoplasms
KW  - Aged
KW  - Genes, BRCA1
KW  - Germ-Line Mutation
KW  - Trastuzumab
KW  - Adult
KW  - Humans
KW  - BRCA2 Protein
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Middle Aged
KW  - Genes, BRCA2
KW  - Receptor, ErbB-2
KW  - Piperazines
KW  - Female
KW  - Treatment Outcome
KW  - BRCA1 Protein
KW  - Phthalazines
TI  - Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study
TY  - research article
VL  - 77
ER  -